Abstract
The National Lipid Association (NLA) recently released recommendations for the treatment of dyslipidemias. These recommendations have commonalities and differences with those of other major societies with respect to risk assessment, lifestyle therapy, targets of therapy, and the use of non-statin agents. In this review, we compare the basic elements of the guidelines from each major society to provide clinicians with a comprehensive document reviewing the key principles of each.
MeSH terms
-
Anticholesteremic Agents / therapeutic use*
-
Disease Management
-
Dyslipidemias / diagnosis
-
Dyslipidemias / therapy*
-
Fatty Acids, Omega-3 / therapeutic use
-
Fibric Acids / therapeutic use
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
-
Niacin / therapeutic use
-
Patient Care Planning
-
Practice Guidelines as Topic*
-
Risk Assessment
-
Risk Reduction Behavior
-
Societies, Medical
Substances
-
Anticholesteremic Agents
-
Fatty Acids, Omega-3
-
Fibric Acids
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Niacin